Selected research
Industry Research
Coccidiosis Vaccines Industry Research Report 2026
Market perspective
The global Coccidiosis Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Coccidiosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Coccidiosis Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Coccidiosis Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Coccidiosis Vaccines include Biopharm, Bioproperties, Boehringer Ingelheim, Ceva Santé Animale, HIPRA, Huvepharma, MSD Animal Health, Nisseiken and Vaxxinova, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Coccidiosis Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Coccidiosis Vaccines Market by Company
Biopharm
Bioproperties
Boehringer Ingelheim
Ceva Santé Animale
HIPRA
Huvepharma
MSD Animal Health
Nisseiken
Vaxxinova
Foshan Standard Biotech
Guangdong Winsun Bio-pharmaceutical
Hlinte
Qilu Qingda Bio-Pharmaceutical
Skystar Bio-pharm
Coccidiosis Vaccines Segment by Type
Attenuated Vaccines
Non-attenuated Vaccines
Coccidiosis Vaccines Segment by Application
Poultry
Rabbit
Others
Coccidiosis Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coccidiosis Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Coccidiosis Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coccidiosis Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Coccidiosis Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Coccidiosis Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Coccidiosis Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Attenuated Vaccines
- Non-attenuated Vaccines
Applications
- Poultry
- Rabbit
- Others
Companies covered
- Biopharm
- Bioproperties
- Boehringer Ingelheim
- Ceva Santé Animale
- HIPRA
- Huvepharma
- MSD Animal Health
- Nisseiken
- Vaxxinova
- Foshan Standard Biotech
- Guangdong Winsun Bio-pharmaceutical
- Hlinte
- Qilu Qingda Bio-Pharmaceutical
- Skystar Bio-pharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Coccidiosis Vaccines Market Size (2021-2032)
- 2.2.2 Global Coccidiosis Vaccines Sales (2021-2032)
- 2.2.3 Global Coccidiosis Vaccines Market Average Price (2021-2032)
- 2.3 Coccidiosis Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Attenuated Vaccines
- 2.3.3 Non-attenuated Vaccines
- 2.4 Coccidiosis Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Poultry
- 2.4.3 Rabbit
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Coccidiosis Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Coccidiosis Vaccines Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Coccidiosis Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Coccidiosis Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Coccidiosis Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Coccidiosis Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Coccidiosis Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Coccidiosis Vaccines, Established Date
- 3.9 Global Coccidiosis Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biopharm
- 4.1.1 Biopharm Company Information
- 4.1.2 Biopharm Business Overview
- 4.1.3 Biopharm Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biopharm Coccidiosis Vaccines Product Portfolio
- 4.1.5 Biopharm Recent Developments
- 4.2 Bioproperties
- 4.2.1 Bioproperties Company Information
- 4.2.2 Bioproperties Business Overview
- 4.2.3 Bioproperties Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bioproperties Coccidiosis Vaccines Product Portfolio
- 4.2.5 Bioproperties Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim Coccidiosis Vaccines Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Ceva Santé Animale
- 4.4.1 Ceva Santé Animale Company Information
- 4.4.2 Ceva Santé Animale Business Overview
- 4.4.3 Ceva Santé Animale Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ceva Santé Animale Coccidiosis Vaccines Product Portfolio
- 4.4.5 Ceva Santé Animale Recent Developments
- 4.5 HIPRA
- 4.5.1 HIPRA Company Information
- 4.5.2 HIPRA Business Overview
- 4.5.3 HIPRA Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 HIPRA Coccidiosis Vaccines Product Portfolio
- 4.5.5 HIPRA Recent Developments
- 4.6 Huvepharma
- 4.6.1 Huvepharma Company Information
- 4.6.2 Huvepharma Business Overview
- 4.6.3 Huvepharma Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Huvepharma Coccidiosis Vaccines Product Portfolio
- 4.6.5 Huvepharma Recent Developments
- 4.7 MSD Animal Health
- 4.7.1 MSD Animal Health Company Information
- 4.7.2 MSD Animal Health Business Overview
- 4.7.3 MSD Animal Health Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MSD Animal Health Coccidiosis Vaccines Product Portfolio
- 4.7.5 MSD Animal Health Recent Developments
- 4.8 Nisseiken
- 4.8.1 Nisseiken Company Information
- 4.8.2 Nisseiken Business Overview
- 4.8.3 Nisseiken Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Nisseiken Coccidiosis Vaccines Product Portfolio
- 4.8.5 Nisseiken Recent Developments
- 4.9 Vaxxinova
- 4.9.1 Vaxxinova Company Information
- 4.9.2 Vaxxinova Business Overview
- 4.9.3 Vaxxinova Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Vaxxinova Coccidiosis Vaccines Product Portfolio
- 4.9.5 Vaxxinova Recent Developments
- 4.10 Foshan Standard Biotech
- 4.10.1 Foshan Standard Biotech Company Information
- 4.10.2 Foshan Standard Biotech Business Overview
- 4.10.3 Foshan Standard Biotech Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Foshan Standard Biotech Coccidiosis Vaccines Product Portfolio
- 4.10.5 Foshan Standard Biotech Recent Developments
- 4.11 Guangdong Winsun Bio-pharmaceutical
- 4.11.1 Guangdong Winsun Bio-pharmaceutical Company Information
- 4.11.2 Guangdong Winsun Bio-pharmaceutical Business Overview
- 4.11.3 Guangdong Winsun Bio-pharmaceutical Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Guangdong Winsun Bio-pharmaceutical Coccidiosis Vaccines Product Portfolio
- 4.11.5 Guangdong Winsun Bio-pharmaceutical Recent Developments
- 4.12 Hlinte
- 4.12.1 Hlinte Company Information
- 4.12.2 Hlinte Business Overview
- 4.12.3 Hlinte Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Hlinte Coccidiosis Vaccines Product Portfolio
- 4.12.5 Hlinte Recent Developments
- 4.13 Qilu Qingda Bio-Pharmaceutical
- 4.13.1 Qilu Qingda Bio-Pharmaceutical Company Information
- 4.13.2 Qilu Qingda Bio-Pharmaceutical Business Overview
- 4.13.3 Qilu Qingda Bio-Pharmaceutical Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Qilu Qingda Bio-Pharmaceutical Coccidiosis Vaccines Product Portfolio
- 4.13.5 Qilu Qingda Bio-Pharmaceutical Recent Developments
- 4.14 Skystar Bio-pharm
- 4.14.1 Skystar Bio-pharm Company Information
- 4.14.2 Skystar Bio-pharm Business Overview
- 4.14.3 Skystar Bio-pharm Coccidiosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Skystar Bio-pharm Coccidiosis Vaccines Product Portfolio
- 4.14.5 Skystar Bio-pharm Recent Developments
5 Global Coccidiosis Vaccines Market Scenario by Region
- 5.1 Global Coccidiosis Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Coccidiosis Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Coccidiosis Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Coccidiosis Vaccines Sales by Region: 2027-2032
- 5.3 Global Coccidiosis Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Coccidiosis Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Coccidiosis Vaccines Revenue by Region: 2027-2032
- 5.4 North America Coccidiosis Vaccines Market Facts & Figures by Country
- 5.4.1 North America Coccidiosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Coccidiosis Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Coccidiosis Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Coccidiosis Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Coccidiosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Coccidiosis Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Coccidiosis Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Coccidiosis Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Coccidiosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Coccidiosis Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Coccidiosis Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Coccidiosis Vaccines Market Facts & Figures by Country
- 5.7.1 South America Coccidiosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Coccidiosis Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Coccidiosis Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Coccidiosis Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Coccidiosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Coccidiosis Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Coccidiosis Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Coccidiosis Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Coccidiosis Vaccines Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Coccidiosis Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Coccidiosis Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Coccidiosis Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Coccidiosis Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Coccidiosis Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Coccidiosis Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Coccidiosis Vaccines Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Coccidiosis Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Coccidiosis Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Coccidiosis Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Coccidiosis Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Coccidiosis Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Coccidiosis Vaccines Value Chain Analysis
- 8.1.1 Coccidiosis Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Coccidiosis Vaccines Production Mode & Process
- 8.2 Coccidiosis Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Coccidiosis Vaccines Distributors
- 8.2.3 Coccidiosis Vaccines Customers
9 Global Coccidiosis Vaccines Analyzing Market Dynamics
- 9.1 Coccidiosis Vaccines Industry Trends
- 9.2 Coccidiosis Vaccines Industry Drivers
- 9.3 Coccidiosis Vaccines Industry Opportunities and Challenges
- 9.4 Coccidiosis Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst